SABS Insider Trading

Insider Ownership Percentage: 25.95%
Insider Buying (Last 12 Months): $15,821.20
Insider Selling (Last 12 Months): $0.00

SAB Biotherapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at SAB Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

SAB Biotherapeutics Share Price & Price History

Current Price: $3.63
Price Change: Price Decrease of -0.24 (-6.20%)
As of 05/17/2024 01:00 AM ET

This chart shows the closing price history over time for SABS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

SAB Biotherapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/7/2023Eddie Joe SullivanCEOBuy1,740$0.88$1,531.205,232,304View SEC Filing Icon  
11/30/2023Michael KingCFOBuy5,000$0.90$4,500.005,000View SEC Filing Icon  
11/29/2023Samuel J ReichChairmanBuy11,000$0.89$9,790.00219,001View SEC Filing Icon  
9/13/2022Christine E HamiltonDirectorBuy10,000$0.73$7,300.004,993,090View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for SAB Biotherapeutics (NASDAQ:SABS)

7.82% of SAB Biotherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SABS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

SAB Biotherapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/16/2024BVF Inc. IL917,826$4.17M0.1%-90.0%9.944%Search for SEC Filing on Google Icon
2/15/2024BVF Inc. IL9,178,282$6.31M0.2%N/A175.426%Search for SEC Filing on Google Icon
2/14/2024Commodore Capital LP1,831,746$1.26M0.1%N/A35.024%Search for SEC Filing on Google Icon
2/14/2024RTW Investments LP9,178,282$6.31M0.1%N/A175.493%Search for SEC Filing on Google Icon
11/8/2023Pathstone Family Office LLC506,513$0.32M0.0%N/A0.968%Search for SEC Filing on Google Icon
8/9/2023Institutional & Family Asset Management LLC192,027$0.16M0.0%+28.2%0.381%Search for SEC Filing on Google Icon
2/2/2023Silver Oak Securities Incorporated51,941$31K0.0%N/A0.121%Search for SEC Filing on Google Icon
11/7/2022Institutional & Family Asset Management LLC149,774$0.11M0.0%+91.7%0.348%Search for SEC Filing on Google Icon
10/20/2022First PREMIER Bank807,535$0.57M0.2%+23.8%1.877%Search for SEC Filing on Google Icon
8/15/2022LGL Partners LLC23,000$33K0.0%N/A0.054%Search for SEC Filing on Google Icon
8/3/2022AE Wealth Management LLC18,700$27K0.0%N/A0.044%Search for SEC Filing on Google Icon
7/26/2022First PREMIER Bank652,440$0.95M0.3%N/A1.519%Search for SEC Filing on Google Icon
5/9/2022Qube Research & Technologies Ltd24,179$91K0.0%+43.8%0.056%Search for SEC Filing on Google Icon
2/14/2022Radcliffe Capital Management L.P.546,658$5.52M0.1%N/A1.257%Search for SEC Filing on Google Icon
2/14/2022ETF Managers Group LLC13,202$0.11M0.0%N/A0.030%Search for SEC Filing on Google Icon
2/14/2022Institutional & Family Asset Management LLC78,115$0.61M0.1%N/A0.180%Search for SEC Filing on Google Icon
2/10/2022Qube Research & Technologies Ltd16,817$0.13M0.0%N/A0.039%Search for SEC Filing on Google Icon
2/9/2022Wolverine Asset Management LLC6,602$51K0.0%N/A0.015%Search for SEC Filing on Google Icon
2/9/2022Alps Advisors Inc.50,306$0.39M0.0%N/A0.116%Search for SEC Filing on Google Icon
2/3/2022Spectrum Management Group LLC5,030$39K0.0%N/A0.012%Search for SEC Filing on Google Icon
2/1/2022Qube Research & Technologies Ltd16,817$0.13M0.0%N/A0.039%Search for SEC Filing on Google Icon
1/19/2022First PREMIER Bank832,555$6.50M1.7%N/A1.915%Search for SEC Filing on Google Icon
1/18/2022Nadler Financial Group Inc.11,000$86K0.0%N/A0.025%Search for SEC Filing on Google Icon
11/17/2021Tudor Investment Corp Et Al60,000$0.61M0.0%N/A0.406%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
SAB Biotherapeutics logo
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
Read More on SAB Biotherapeutics

Today's Range

Now: $3.63
Low: $3.52
High: $3.79

50 Day Range

MA: $4.48
Low: $3.63
High: $6.00

52 Week Range

Now: $3.63
Low: $3.52
High: $10.50

Volume

12,221 shs

Average Volume

5,749 shs

Market Capitalization

$33.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

Who are the company insiders with the largest holdings of SAB Biotherapeutics?

SAB Biotherapeutics' top insider shareholders include:
  1. Eddie Joe Sullivan (CEO)
  2. Christine E Hamilton (Director)
  3. Samuel J Reich (Chairman)
  4. Michael King (CFO)
Learn More about top insider investors at SAB Biotherapeutics.

Who are the major institutional investors of SAB Biotherapeutics?

SAB Biotherapeutics' top institutional investors include:
  1. BVF Inc. IL — 9.94%
Learn More about top institutional investors of SAB Biotherapeutics stock.

Which institutional investors are selling SAB Biotherapeutics stock?

During the last quarter, SABS stock was sold by these institutional investors:
  1. BVF Inc. IL